Guggenheim assumed coverage on shares of Alumis (NASDAQ:ALMS – Free Report) in a research note published on Tuesday, Marketbeat reports. The firm issued a buy rating and a $32.00 price target on the stock.
Separately, Morgan Stanley started coverage on Alumis in a research note on Tuesday. They set an overweight rating and a $36.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Buy and an average price target of $27.50.
Check Out Our Latest Analysis on Alumis
Alumis Price Performance
About Alumis
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Stories
- Five stocks we like better than Alumis
- Learn Technical Analysis Skills to Master the Stock Market
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Profitably Trade Stocks at 52-Week Highs
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Quiet Period Expirations Explained
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
